Full Text View
Tabular View
No Study Results Posted
Related Studies
Safety and Effectiveness of NXY-059 for the Treatment of Patients Who Have Suffered From a Stroke
This study has been completed.
Study NCT00061022   Information provided by AstraZeneca
First Received: May 20, 2003   Last Updated: March 18, 2009   History of Changes

May 20, 2003
March 18, 2009
May 2003
 
Global disability on modified Rankin scale at 90 days.
Same as current
Complete list of historical versions of study NCT00061022 on ClinicalTrials.gov Archive Site
  • NIH stroke scale
  • Barthel Index
  • Stroke Impact Scale
  • EQ-5D all at 90 days
  • Safety outcomes
  • NIH stroke scale (termed “co-primary” in study protocol),
  • Barthel Index,
  • Stroke Impact Scale,
  • EQ-5D all at 90 days,
  • Safety outcomes.
 
Safety and Effectiveness of NXY-059 for the Treatment of Patients Who Have Suffered From a Stroke
SAINT (Stroke - Acute Ischemic - NXY Treatment) A Double Blind, Randomized, Placebo Controlled, Parallel Group, Multicenter, Phase IIb/III Study to Assess the Efficacy and Safety of Intravenous NXY-059 in Acute Ischemic Stroke

This study will determine if NXY-059 will improve recovery from an acute stroke. The study is designed to look at both overall recovery and recovery of motor function, for example muscle strengthen and coordination.

 
Phase II, Phase III
Interventional
Treatment, Randomized, Double-Blind, Placebo Control, Factorial Assignment, Safety/Efficacy Study
  • Cerebral Stroke
  • Stroke, Acute
  • Cerebrovascular Stroke
  • Ischemic Attack, Transient
Drug: NXY-059
 
Shuaib A, Lees KR, Lyden P, Grotta J, Davalos A, Davis SM, Diener HC, Ashwood T, Wasiewski WW, Emeribe U; SAINT II Trial Investigators. NXY-059 for the treatment of acute ischemic stroke. N Engl J Med. 2007 Aug 9;357(6):562-71.

*   Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.
 
Completed
3200
September 2006
 

Inclusion Criteria:

  • Males and females
  • Acute ischemic stroke with limb weakness
  • Onset of symptoms within 6 hours
  • Full functional independence prior to the present stroke

Exclusion Criteria:

  • Unconsciousness
  • Subjects who are unlikely to complete the infusion of investigational product and/or are unlikely to undergo active medical management during that period due to a severe clinical condition.
  • Severe illness with life expectancy less than 6 months.
  • Known severe kidney disorder.
  • Current known alcohol or illicit drug abuse or dependence.
  • Pregnant or breast-feeding.
  • Treatment with acetazolamide and methotrexate is not permitted during the infusion
  • Participation in a previous clinical study within 30 days.
  • Meets all other exclusion criteria.
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States,   Argentina,   Australia,   Austria,   Belgium,   Brazil,   Bulgaria,   Canada,   Chile,   China,   Czech Republic,   France,   Germany,   Greece,   Hong Kong,   Hungary,   Israel,   Korea, Republic of,   Mexico,   New Zealand,   Philippines,   Poland,   Portugal,   Russian Federation,   Slovakia,   South Africa,   Spain,   Switzerland,   Taiwan,   United Kingdom
 
NCT00061022
 
SA-NXY-0007, 007, SAINT 2
AstraZeneca
 
Study Director: AstraZeneca NXY-059 Medical Science Director, MD AstraZeneca
AstraZeneca
March 2009

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP